Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10175324 | 1.00 | MGLL (0.41) | MGLLPLK1 | |
| SCHEMBL1117827 | 1.00 | MGLL (0.41) | MGLLPLK1 | |
| SCHEMBL8825516 | 0.96 | POLB (0.40) | — | |
| SCHEMBL8825520 | 0.96 | POLB (0.40) | — | |
| SCHEMBL28346561 | 0.92 | SMYD2 (0.40) | — | |
| SCHEMBL30563746 | 0.88 | SMYD2 (0.36) | MGLL | |
| SCHEMBL9886817 | 0.83 | MEN1 (0.47) | MGLL | |
| SCHEMBL20500291 | 0.83 | MEN1 (0.47) | MGLL | |
| SCHEMBL7203588 | 0.83 | MEN1 (0.47) | MGLL | |
| SCHEMBL1564475 | 0.83 | SMYD2 (0.39) | PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160176906-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-06-23 | — | — | US | disclosed |
| US-9248140-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2016-02-02 | — | — | US | disclosed |
| US-20150328239-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2015-11-19 | — | — | US | disclosed |
| US-9018381-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-04-28 | — | — | US | disclosed |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (UK) | 2013-11-21 | — | — | US | disclosed |
| US-20120035134-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035134-A1 | CHEMICAL COMPOUNDS | BCL2, BCL2L1, BAX | MGLL 3527/4885PLK1 311/4885 |
| US-20150328239-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | MGLL 3527/4885PLK1 311/4885 |
| US-20160176906-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | MGLL 3527/4885PLK1 311/4885 |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | BCL2, BAX, BCLAF1 | MGLL 3037/4885PLK1 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.